Novel Therapies for the Treatment of Advanced Prostate Cancer

Opinion statement In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents ar...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in oncology 2013-03, Vol.14 (1), p.109-126
Main Authors: Clarke, J. M., Armstrong, A. J.
Format: Article
Language:English
Subjects:
Androgen Antagonists - therapeutic use
Castration
Epigenetics
Genitourinary Cancer (R Pili
Genomes
Humans
Immunotherapy
Intracellular signalling
Male
Medicine
Medicine & Public Health
Metastases
Microenvironments
Oncology
Orchiectomy
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - genetics
Section Editor
Signal Transduction
Steroid 17-alpha-Hydroxylase - antagonists & inhibitors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion statement In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.
ISSN:1527-2729
1534-6277
1534-5277
DOI:10.1007/s11864-012-0222-4